Florence Healthcare announced that it has acquired VersaTrial, a cutting-edge clinical trial solutions provider. This strategic move amplifies Florence Healthcare’s core mission to enable every study site to maximize its efficiency and capacity, effectively transforming the landscape of clinical research operations.
The acquisition unites two site-centric trailblazers in the eClinical space, bringing together complementary strengths to create a more powerful solution for research sites, CROs, and sponsors. Florence Healthcare, with its footprint of over 18,000 connected research sites in 55+ countries, will integrate VersaTrial’s innovative features designed to reduce tech burden, speed up feasibility response times, and enhance communication across frequently changing study personnel.
Ryan Jones, CEO of Florence Healthcare, said, “This acquisition marks a significant moment for our industry. Together, VersaTrial and Florence have the opportunity to help every trial site do their best work, and get this industry closer to maximizing efficiency and capacity for every research site.”
Mike Wenger, CEO of VersaTrial, echoed these sentiments, stating, “Joining forces with Florence Healthcare is a monumental leap forward for VersaTrial and for research sites globally. Florence Healthcare’s proven track record digitizing clinical trial sites globally at scale will undoubtedly enhance the impact of our solutions. Together, we’re poised to drive meaningful improvements in trial speed and patient outcomes.”
As a result of the combined capabilities of Florence Healthcare and VersaTrial, sites, sponsors and CROs will also benefit from the expanded range of services offered by Florence Healthcare and VersaTrial. With real-time site connectivity, sites, sponsors and CROs will be able to manage clinical studies more efficiently, reduce data duplication, improve site readiness, and enhance communication with sites.